On that early, early remdesivir data
Whether or not remdesivir works, one thing is clear: Gilead is moving fast.
On Friday, the company published preliminary data on the antiviral’s effects on Covid-19 in NEJM. And while the company's speed is impressive, the small study raised more than a few eyebrows in the scientific community. The data showed that two-thirds of the 53 patients studied improved while taking the drug. But the data weren't from a randomized, controlled study, and thus many consider the release premature — even irresponsible.
On Friday, the company published preliminary data on the antiviral’s effects on Covid-19 in NEJM. And while the company's speed is impressive, the small study raised more than a few eyebrows in the scientific community. The data showed that two-thirds of the 53 patients studied improved while taking the drug. But the data weren't from a randomized, controlled study, and thus many consider the release premature — even irresponsible.
In yet another open letter, Gilead CEO Daniel O’Day wrote that the company does “recognize the limitations of these compassionate use data from a purely investigational perspective.” He also said more (preliminary) data are set to come at the end of April.
And, for what it's worth, not everyone saw the first data dump as meaningless.
.png)
No hay comentarios:
Publicar un comentario